Milestone Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.9572
- Today's High:
- $3.0999
- Open Price:
- $3.07
- 52W Low:
- $2.68
- 52W High:
- $9.847
- Prev. Close:
- $3.07
- Volume:
- 53363
Company Statistics
- Market Cap.:
- $90.13 million
- Book Value:
- 0.941
- Revenue TTM:
- $6 million
- Operating Margin TTM:
- -1012.12%
- Gross Profit TTM:
- $5 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -40.31%
- Return on Equity TTM:
- -92.43%
Company Profile
Milestone Pharmaceuticals Inc had its IPO on 2019-05-09 under the ticker symbol MIST.
The company operates in the Healthcare sector and Biotechnology industry. Milestone Pharmaceuticals Inc has a staff strength of 39 employees.
Stock update
Shares of Milestone Pharmaceuticals Inc opened at $3.07 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.96 - $3.1, and closed at $3.09.
This is a +0.65% increase from the previous day's closing price.
A total volume of 53,363 shares were traded at the close of the day’s session.
In the last one week, shares of Milestone Pharmaceuticals Inc have increased by +14.44%.
Milestone Pharmaceuticals Inc's Key Ratios
Milestone Pharmaceuticals Inc has a market cap of $90.13 million, indicating a price to book ratio of 1.7242 and a price to sales ratio of 86.8579.
In the last 12-months Milestone Pharmaceuticals Inc’s revenue was $6 million with a gross profit of $5 million and an EBITDA of $-60643000. The EBITDA ratio measures Milestone Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Milestone Pharmaceuticals Inc’s operating margin was -1012.12% while its return on assets stood at -40.31% with a return of equity of -92.43%.
In Q2, Milestone Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Milestone Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.36 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Milestone Pharmaceuticals Inc’s profitability.
Milestone Pharmaceuticals Inc stock is trading at a EV to sales ratio of 38.9171 and a EV to EBITDA ratio of -0.931. Its price to sales ratio in the trailing 12-months stood at 86.8579.
Milestone Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $97.02 million
- Total Liabilities
- $6.81 million
- Operating Cash Flow
- $-28031000.00
- Capital Expenditure
- $31000
- Dividend Payout Ratio
- 0%
Milestone Pharmaceuticals Inc ended 2024 with $97.02 million in total assets and $0 in total liabilities. Its intangible assets were valued at $97.02 million while shareholder equity stood at $40.41 million.
Milestone Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $6.81 million in other current liabilities, 260169000.00 in common stock, $-297334000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $32.59 million and cash and short-term investments were $87.59 million. The company’s total short-term debt was $522,000 while long-term debt stood at $48.07 million.
Milestone Pharmaceuticals Inc’s total current assets stands at $94.57 million while long-term investments were $0 and short-term investments were $55.00 million. Its net receivables were $1.58 million compared to accounts payable of $2.40 million and inventory worth $-483000.00.
In 2024, Milestone Pharmaceuticals Inc's operating cash flow was $-28031000.00 while its capital expenditure stood at $31000.
Comparatively, Milestone Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.09
- 52-Week High
- $9.847
- 52-Week Low
- $2.68
- Analyst Target Price
- $14.2
Milestone Pharmaceuticals Inc stock is currently trading at $3.09 per share. It touched a 52-week high of $9.847 and a 52-week low of $9.847. Analysts tracking the stock have a 12-month average target price of $14.2.
Its 50-day moving average was $3.13 and 200-day moving average was $3.63 The short ratio stood at 6.51 indicating a short percent outstanding of 0%.
Around 100.1% of the company’s stock are held by insiders while 6541.2% are held by institutions.
Frequently Asked Questions About Milestone Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.